Please assess the completion status of the following clinical trial:

Trial Title: Vedolizumab Induction May Prevent Celiac Enteritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must meet the following criteria for study entry:~* Adult patients with Celiac Disease (CD)~* Without any additional co-morbidities~* Normal renal and hepatic function~* Diagnosis of CD established at least 6 months prior to trial with diagnostic serology, genetic profile, endoscopic appearance and histopathology report In histologic and serologic remission (defined as MARSH 0 and negative anti-tissue transglutaminase, etc.) following a gluten free diet~* Naïve to treatment with vedolizumab~* Able and willing to provide written informed consent~* Eligibility criteria for laboratory profiles - healthy patient normal laboratory reference values~  * WBC 4.5-12.0 k/UL~ * Platelet count- 140-415 k/UL~ * Hemoglobin- 11.0-17.4 %g/dL~ * Renal Function-~ * Creatinine- 0.5-1.3 mg/dL~ * BUN- 5-20 mg/dL~ * Hepatic Function~ * Albumin - 3.3-5.0 g/dL~ * INR- 0.9-1.1~ * AST- 0-37 U/L~ * ALT- 0-40 U/L~ * Total Bilirubin- 0.1-1.3 mg/dL~ * Alk Phos- 35-150 U/L~Exclusion Criteria:~* Patients who meet any of the following criteria will be excluded from study entry:~* Abnormal MARSH score on enrollment histopathology~* Elevated celiac serologies (anti-tissue transglutaminase, etc.)~* Current use of biologics or immunomodulators Adalimumab, infliximab, Ustekinumab, Golimumab, Tocilizumab, Certolizumab, Etanercept, Rituximab, Anakinra, Abatacept, Tofacitinib, Methotrexate, Azathioprine, 6-MP.~* Current use of immunosuppressive therapy including intermittent systemic corticosteroids within two months of vedolizumab induction~* History of intestinal lymphoma (MALToma, etc.)~* History of cancer including hematologic malignancy, solid tumors, carcinoma in situ, etc.~* Pregnant or lactating~* Fertile females will require at least one form of birth control~* Lack of peripheral venous access~* Inability to comply with study protocol, in the opinion of the investigator~* Neurological conditions which may interfere with monitoring for PML~* History of demyelinating disease or history of major neurological disease~* History of alcohol, drug or chemical abuse \< 6 months prior to screening~* History of active tuberculosis (TB) or a positive screening test for latent mycobacterium tuberculosis infection~* Positive PPD= \> 10 mm or \> 5mm in patients on 15 mg or more of prednisone~* History of BCG vaccination should be screened using Quantiferon TB Gold test~* An Indeterminate Quantiferon test will require a chest X-ray to rule out active TB and consultation with an infectious disease specialist to confirm the risk of latent~* TB is low and that patients can be safely enrolled in the trial~* History of recurrent opportunistic infections and/or of severe or disseminated viral infections~* Active autoimmune disease~* Active inflammatory bowel disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Vedolizumab (Type: EXPERIMENTAL): Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues